Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)

Next Previous
Trial Profile

A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Cetuximab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 30 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 06 Feb 2013 Planned End Date changed from 1 Jan 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
  • 14 Nov 2012 Planned End Date changed from 1 Sep 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top